chr9:5450525:> Detail (hg19) (CD274)

Information

Genome

Assembly Position
hg19 chr9:5,450,525-5,470,547
hg38 chr9:5,450,525-5,470,547 

HGVS

Type Transcript Protein
Summary

MGeND

Clinical significance
Variant entry
GWAS entry
Disease area statistics Show details

Frequency

[No Data.]

Prediction

[No Data.]

ClinVar

Clinical Significance
Review star [No Data.]
Show details
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
Disease Drug EL ET ED CS VO TR Pubmed Links
lung non-small cell carcinoma Atezolizumab,Nivolumab,Avelumab,Pembrolizumab B Predictive Supports Sensitivity/Response N/A 4 26918451 Detail
lung non-small cell carcinoma Atezolizumab B Predictive Supports Sensitivity/Response N/A 4 26970723 Detail
thyroid gland papillary carcinoma B Prognostic Supports Poor Outcome N/A 3 27086918 Detail
stomach carcinoma B Prognostic Supports Better Outcome N/A 3 27009855 Detail
cancer Nivolumab B Predictive Supports Sensitivity/Response Somatic 2 22658127 Detail
Merkel cell carcinoma Pembrolizumab B Predictive Does Not Support Sensitivity/Response Somatic 2 27093365 Detail
melanoma Ipilimumab,Nivolumab B Predictive Does Not Support Sensitivity/Response Somatic 3 23724867 Detail
lung non-small cell carcinoma Pembrolizumab B Predictive Supports Sensitivity/Response N/A 3 27718847 Detail
head and neck squamous cell carcinoma Radiation Therapy B Predictive Supports Resistance N/A 4 28476872 Detail
breast cancer B Prognostic Supports Poor Outcome N/A 2 28079291 Detail
breast cancer B Prognostic Supports Poor Outcome N/A 3 28430626 Detail
cancer B Prognostic Supports Better Outcome N/A 2 28453554 Detail
lung non-small cell carcinoma Durvalumab,Atezolizumab,Avelumab,Nivolumab,Pembrolizumab B Predictive Supports Sensitivity/Response N/A 4 28472902 Detail
cancer B Prognostic Supports Poor Outcome N/A 4 28471952 Detail
lung non-small cell carcinoma Pembrolizumab B Predictive Supports Sensitivity/Response Somatic 4 25891174 Detail
lung non-small cell carcinoma B Prognostic Does Not Support Poor Outcome Somatic 4 26664143 Detail
lung squamous cell carcinoma B Prognostic Supports Better Outcome N/A 3 26313362 Detail
ovarian serous carcinoma B Prognostic Supports Better Outcome N/A 3 26625204 Detail
melanoma Pembrolizumab,Nivolumab B Predictive Supports Sensitivity/Response N/A 4 26086854 Detail
lung non-small cell carcinoma Nivolumab,Pembrolizumab B Predictive Supports Sensitivity/Response N/A 4 26086854 Detail
lung non-small cell carcinoma B Prognostic Supports Poor Outcome N/A 2 26771872 Detail
DisGeNET
[No Data.]
Annotation

Annotations

DescrptionSourceLinks
Meta-Analysis of PD-L1 (CD274) Expression Status in 914 patients (7 studies) and response to PD-1/PD... CIViC Evidence Detail
Exploratory biomarker analysis from a phase-II randomized trial comparing atezolizumab (PD-L1) and d... CIViC Evidence Detail
Immunohistochemical analyses of PD-L1 protein was retrospectively performed on 251 archived FFPE sur... CIViC Evidence Detail
465 gastric cancer samples and 15 corresponding liver metastases underwent IHC for PD1/PD-L1 protein... CIViC Evidence Detail
Trial NCT00730639 tested monoclonal antibody nivolumab against the PD-1 immune checkpoint receptor i... CIViC Evidence Detail
Patients with Merkel Cell Carcinoma (n=26) were enrolled to receive pembrolizumab. Of these patients... CIViC Evidence Detail
A clinical trial of 86 patients evaluated concurrent (n=53) or sequential (n=33) treatment of ipilim... CIViC Evidence Detail
This open-label, randomized, phase-3 clinical trial compared pembrolizumab to chemotherapy in treati... CIViC Evidence Detail
Radiation-resistant cell lines exhibited upregulation and increased activation of Axl, PI3 kinase si... CIViC Evidence Detail
A meta-analysis of the role of PD-L1 expression in breast cancer found nine relevant studies with a ... CIViC Evidence Detail
In this meta-analysis, 5 studies totalling 2,546 cases were combined to assess the prognostic associ... CIViC Evidence Detail
PD-L1 is not only expressed in tumor cells (TCs) but also upregulated in tumor-infiltrating immune c... CIViC Evidence Detail
In this meta-analysis of 14 studies with 2857 patients, the immunotherapy response rate was higher a... CIViC Evidence Detail
A meta analysis of 60 research studies involving 10,310 solid tumors indicated that CD274 over expre... CIViC Evidence Detail
PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab. CIViC Evidence Detail
This meta-analysis did not find a significant connection between expression of PD-L1 and overall sur... CIViC Evidence Detail
In this study, PD-L1 expression (measured by IHC) was associated with better overall survival in the... CIViC Evidence Detail
High expression of PD-L1 and PD-1 were associated with a favorable prognosis in patients with high g... CIViC Evidence Detail
Based on a meta-analysis of 20 trials (1475 patients), of which 7 studies (636 patients) included me... CIViC Evidence Detail
Based on a meta-analysis of 20 trials (1475 patients), PD-L1 expression was associated with a higher... CIViC Evidence Detail
74 patients with stage III NSCLC treated with concurrent chemoradiotherapy were retrospectively anal... CIViC Evidence Detail

Overlapped Transcript Coordinates

Gene Transcript ID Exon Number Chromosome Start Stop Type Amino Mutation Transcript Position Links

Overlapped Transcript

Gene Transcript ID Chromosome Start Stop Links
Gene
-
Genome
hg19
Position
chr9:5,450,525-5,470,547
Variant Type
snv
Variant (CIViC) (CIViC Variant)
EXPRESSION
Transcript 1 (CIViC Variant)
ENST00000381577.3
Variant URL (CIViC Variant)
https://civic.genome.wustl.edu/links/variants/276
Genome browser